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Abstract
Pentraxin 3 (PTX3) and C-reactive protein (CRP) levels were measured in the first trimester of pregnancy in women who
subsequently developed preeclampsia (PE, n16) and fetal growth restriction (FGR, n12) requiring iatrogenic delivery
before 37 weeks, and those who had uncomplicated pregnancies delivering at term (n60). Mean PTX3 levels were
significantly higher in women who subsequently developed PE (7.31 ng/ml, SD4.12) when compared to those with
normal pregnancy outcome (4.92 ng/ml, SD1.94, p0.0046). There were no significant differences between PTX3 levels
in women with FGR (4.82 ng/ml, SD2.35) compared to normal pregnancy outcome (p0.88). The median CRP levels
did not vary significantly between the three groups (p0.26). PTX3 levels in women who subsequently develop PE are
already elevated in the first trimester, but not in those that develop FGR. This supports the hypothesis of an excessive
maternal inflammatory response to pregnancy in the etiology of PE.
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Introduction
The etiology of preeclampsia (PE) and fetal growth
restriction (FGR) remains unclear despite their ob-
vious importance from the public health perspective
as leading causes of maternal and perinatal mortality
worldwide. What is known is that disorders of
trophoblast development, endothelial activation, an-
giogenesis, and abnormal oxidative stress may con-
tribute to the etiology or pathophysiology of PE (1).
The maternal serum markers related to these mechan-
isms have been evaluated for the early identification of
women at high risk of developing PE (2).
There is increasing evidence that an abnormal
immunological or inflammatory response between
the developing trophoblast and maternal decidua
may have an important role in the etiology of PE (1).
Pentraxin 3 (PTX3) is a recently described inflam-
matory molecule which belongs to the same family
as C-reactive protein (CRP). It is expressed in
response to inflammatory stimuli by a variety of
cells, including endothelial cells, monocytes, macro-
phages, and fibroblasts (3). PTX3 is known to be
present in receptive endometrium, and abnormal
expression is implicated in pregnancy failure (4).
Previous studies have shown that maternal PTX3
levels are significantly higher in women with estab-
lished PE in the third trimester when compared to
those with normal pregnancies (5,6). The aim of this
study is to compare first trimester serum levels of
PTX3 in women who subsequently developed pre-
term PE to those requiring preterm delivery for FGR
or with a normal pregnancy outcome.
Material and methods
This is a prospective nested casecontrol study from a
larger ongoing study examining first trimester
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ultrasound and serum markers for PE. Unselected
women with singleton pregnancies attending St
George’s Hospital for their first trimester ultrasound
scan between 11 and 14 weeks of gestation were
invited to participate. The study protocol was ap-
proved by the medical ethics committee of the hospital
and written informed consent was obtained from each
participant. Mothers with pre-existing medical dis-
orders or receiving drug therapy were excluded from
the study. Maternal blood was collected and stored at
the time of the ultrasound examination. Maternal
demographic characteristics and ultrasound findings
were entered onto a computerized database at the time
of the ultrasound examination. Data on pregnancy
outcome were entered onto the same database when
these became available from the delivery records. A
database search was performed to identify all cases
meeting the inclusion criteria, and their stored blood
samples were then retrieved.
Maternal blood samples were analyzed from three
groups of patients: those with pregnancies compli-
cated by preterm PE with normal fetal growth; and
those with preterm FGR in the absence of PE. For
the purpose of this study, only cases of PE and FGR
requiring delivery before 37 weeks of gestation were
included. For every case, the next two cases with full
term uncomplicated pregnancies with normal fetal
growth were selected as controls.
PE was defined according to the guidelines of the
International Society for the Study of Hypertension
in Pregnancy. This requires two recordings of
systolic blood pressure ]140/90 mMHg at least 4
h apart in a previously normotensive woman, and
proteinuria of 300 mg or more in 24 h, or two
readings of at least 2 on dipstick analysis of
midstream or catheter urine specimens if no 24 h
collection is available. FGR was defined as a birth
weight below the fifth percentile for gestational age
necessitating delivery because of abnormal tests of
fetal well-being (abnormal umbilical artery pulsati-
lity index [95th centile], abnormal biophysical
profile, or abnormal cardiotocography). Uncompli-
cated pregnancies were defined as pregnancies which
remained normotensive throughout gestation and
resulted in full-term delivery of a healthy infant with
appropriate weight for gestational age.
Maternal blood samples were centrifuged and
serum was stored at 808C for up to two years until
analysis. Analysis was performed at the Istituto
Clinico Humanitas, where the researchers were
blinded to the pregnancy outcome. The Sandwich
ELISA for PTX3 was performed as previously
described (7). The PTX3 ELISA system has a
detection limit of 0.1 ng/mL with an intra-assay
and inter-assay coefficient of variation (CV) of
B5%. Serum levels of CRP were measured using
the ultrasensitive latex immunoassay CRP Vario
(Abbott Diagnostics Europe) with the intra- and
inter-assay CV both B10%. All assays were per-
formed without knowledge of pregnancy outcome.
Statistical analysis
Sample size was calculated on the basis that the
difference in serum PTX3 levels between women
with PE and controls would be at least two-fold (5).
Setting type I and II errors at 0.05 and 0.20,
respectively, we calculated the required sample size
should be at least 10 cases of PE and FGR. Data in
the three groups were analyzed for evidence of non-
normality using the ShapiroWilk W test. Data were
presented as median and interquartile range (IQR)
if non-parametric or mean and standard deviation
(SD) if parametric. The three groups were compared
using the FisherFreemanHalton exact test for
dichotomous variables, and ANOVA or Kruskal
Wallis test for continuous variables. If there was
evidence of difference between the three groups,
subgroup analysis between pairs of outcomes were
performed using the t-test or MannWhitney U test.
For multiple comparisons, statistically significant
results were confirmed using Scheffe´ test. Two-sided
p-values are reported throughout.
Results
Sixteen cases of PE, 14 of FGR and 60 controls were
identified. Assay results were only available from 12
women with FGR. There were no significant differ-
ences in maternal age, parity, and BMI between the
three groups of patients (Table I). There were
significantly more Afro-Caribbean women in the
group that later developed preterm PE. The gesta-
tional age at delivery and birth weight in pregnancies
complicated by either PE or FGR was lower than in
normal pregnancies, as preterm delivery was in-
cluded in the definition of these outcomes (Table I).
There were significant differences in mean PTX3
levels between the three groups (Figure 1, ANOVA
F6.03, p0.0036). Mean PTX3 levels were
significantly higher in women who subsequently
developed preterm PE (7.31 ng/ml, SD4.12)
compared to those with normal pregnancy outcome
(4.92 ng/ml, SD1.94, p0.0046). There were no
significant differences between PTX3 levels in wo-
men with preterm FGR (4.82 ng/ml, SD2.35)
compared to those with normal pregnancy outcome
(p0.88). Scheffe´’s test was used to confirm these
differences were not due to multiple comparisons
(normal versus PE, p0.0046, FGR versus normal,
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above the 95th percentile for PTX3 in normal
pregnancy (8.55 ng/ml) were found in 5/16 (31%)
of those that subsequently developed PE. There was
no significant correlation between PTX3 and BMI
overall, or in any of the three groups (p0.174).
There were no significant differences in the
median CRP levels (KruskalWallis T2.73, p
0.26) between the women with normal pregnancy
outcome (0.30 mg/dL, IQR 0.171.37), preterm PE
(0.37 mg/dL, IQR 0.201.21), and preterm FGR
(0.24 mg/dL, IQR 0.180.65). No correlation be-
tween CRP and PTX3 was seen in women with
normal outcome (r0.02, p0.88).
Discussion
The data of this study suggest that abnormally high
maternal serum long PTX3 levels in early pregnancy
are associated with the subsequent development of
preterm PE, but not FGR. PTX3 is a member of the
pentraxin family, which includes CRP and serum
amyloid P component (SAP). The cross-species
evolutionary conservation of PTX3, in contrast to
CRP and SAP, suggests an important role for this
molecule. PTX3 appears to have a major role in
resistance against selected pathogens by acting as a
predecessor of antibodies, recognizing microbes,
activating complement, and facilitating pathogen
recognition by phagocytes. However, recent animal
studies have also shown coordinated temporal PTX3
expression at uterine sites during implantation (4).
Furthermore, deletion of this gene results in early
pregnancy failure suggesting that PTX3 plays a
crucial role in implantation and decidualization (4).
In the human, PTX3 is seen in receptive endome-
trium, and in-vitro co-culture studies of trophoblast
and uterine stromal cells have demonstrated signifi-
cant upregulation of inflammatory genes, especially
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Table I. Maternal demographic characteristics and pregnancy outcomes in the study groups.
Normal (n60) FGR (n12) PE (n16)
n or
median
Percentage
(%) or IQR
n or
median
Percentage
(%) or IQR
n or
median
Percentage
(%) or IQR p*
Parity 0.30
Nulliparous 32 53% 6 50% 5 31%
Parous 28 47% 6 50% 11 69%
Race 0.017
Caucasian 49 82% 7 58% 9 56%
African 2 3% 2 17% 5 31%
Asian 3 5% 2 17% 1 6%
Other 6 10% 1 8% 1 6%
Age (years) 32.6 29.15.8 33.3 28.55.9 34.7 28.56.9 0.72
BMI 22.9 21.15.1 24.2 22.88.6 25.2 21.98.5 0.17
Birth weight (grams) 3,390 3,1063,700 1,514 1,3493,819 2,495 2,3152,640 **
Birth weight (centile) 43.6 24.86.0 1.3 0.30.8 21.9 8.632.0 **
Gestational age at delivery (weeks) 403 393411 344 333353 363 361364 **
Note: BMIbody mass index; IQRinterquartile range; FGRfetal growth restriction; PEpreeclampsia.
*p-values comparing the three groups were calculated using the FisherFreemanHalton exact test for dichotomous variables and Kruskal
Wallis test for continuous variables.
**p-values for birth weight and gestational age are not reported as these variables were used to define the three groups.
Figure 1. First trimester maternal serum PTX3 levels (ng/ml) in
women with normal outcome, fetal growth restriction (FGR), and
those that developed preeclampsia (PE).
PTX3 and prediction of preeclampsia and FGR 3
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IL8 and PTX3 (8,9). This suggests that successful
implantation may rely on the modulation of the
immune environment of the decidua by the tropho-
blast to ensure an enriched cytokine/chemokine
environment. The abnormal pro-inflammatory ma-
ternal status (IL1 and TNF-a), pre-existing en-
dothelial damage, and excess of oxidized LDL seen
in the first trimester in women who subsequently
develop PE may all induce PTX3 elevation (3,10).
Further studies are needed to address the potential
involvement of PTX3 in the pathogenesis of sub-
sequent poor trophoblast invasion. Differences in
placental histology seen between PE and FGR may
explain the lack of PTX3 elevation in FGR cases,
suggesting that abnormal maternal immune re-
sponses may not be responsible for the placental
abnormalities seen in FGR (11). The additional
study finding that neither preterm PE nor FGR have
elevated CRP levels is consistent with most but not
all previous studies (12). The lack of correlation
between CRP and PTX3 suggest that pregnancy
may exert independent mechanisms for modulating
these inflammatory markers.
One of the aims of antenatal care has been early
identification of women at risk of adverse pregnancy
outcomes such as PE. There is evidence from a
number of trials that aspirin or calcium therapy may
be particularly effective when started in the early
part of pregnancy, and this has highlighted the need
for identifying high-risk women in the first trimester.
The finding of this study that PTX3 is significantly
higher in women with subsequent PE as early as the
first trimester could make this a useful and biologi-
cally plausible marker. PTX3 unlike uterine artery
Doppler, PlGF, VEGF, sFLt-1, or PP13, is a marker
of maternal inflammatory response rather than
placental function, and therefore may be an inde-
pendent, synergistic biomarker for PE (5). Further
evaluation of PTX3 in the prediction of PE should
be carried out, and its relationship to uterine artery
Doppler and other maternal serum markers exam-
ined.
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